Dr Reddy's Q4 Profit Plunges 86% to ₹220 Cr on 12% Revenue Drop

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Dr Reddy's Q4 Profit Plunges 86% to ₹220 Cr on 12% Revenue Drop
Overview

Dr Reddy's Laboratories reported a steep 86% fall in its fourth-quarter net profit, which dropped to ₹220 crore for the period ending March 31, 2025. Consolidated revenue fell 12% to ₹7561 crore. The company cited lower sales of a key drug and one-off expenses for the decline. Leadership emphasized a focus on cost efficiencies and portfolio optimization to improve profitability.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Reasons for Profit Drop

The sharp drop in Dr Reddy's fourth-quarter profit was mainly due to lower sales of lenalidomide, a key revenue driver. The company also incurred one-off expenses that reduced earnings. G V Prasad, Co-Chairman & MD, stated the results were affected by market challenges. He mentioned that strong performance in the branded business and favorable currency movements provided some support, but the overall impact was significant.

Strategy for Future Growth

Despite the quarterly results, Dr Reddy's leadership is focused on improving profitability. Prasad outlined a two-part strategy: boosting the core business with cost savings and refining the product lineup. The company is also investing in growth areas such as biosimilars, consumer health, and new drug development to build long-term value and enhance margins.

Following the results announcement on May 12, 2025, Dr Reddy's shares closed 0.75% lower on the Bombay Stock Exchange, trading at ₹1270.10.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.